GlaxoSmithKline Pharmaceuticals Limited (BOM: 500660)
India
· Delayed Price · Currency is INR 2,456.70
+3.35 (0.14%)
At close: Nov 14, 2024
GlaxoSmithKline Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Net Income | 6,750 | 5,900 | 6,107 | 16,947 | 3,581 | 932.05 | Upgrade
|
| Depreciation & Amortization | 579.43 | 591.43 | 560.73 | 587.16 | 695.71 | 728.98 | Upgrade
|
| Other Amortization | 105.37 | 105.37 | 96.94 | 94.7 | 90.34 | 97.8 | Upgrade
|
| Loss (Gain) From Sale of Assets | -8.89 | -8.89 | -0.28 | -3.24 | 0.59 | -23.34 | Upgrade
|
| Loss (Gain) From Sale of Investments | -487.76 | -487.76 | -307.79 | -5.92 | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | 5.87 | 5.87 | -73.64 | 1.62 | 20.61 | 31.7 | Upgrade
|
| Other Operating Activities | 2,159 | -895.67 | -1,124 | -11,442 | -38.93 | 2,697 | Upgrade
|
| Change in Accounts Receivable | -302.69 | -302.69 | 202.28 | 102.04 | -999.34 | -0.5 | Upgrade
|
| Change in Inventory | -650.78 | -650.78 | 747.25 | 120.03 | -467.93 | -677.17 | Upgrade
|
| Change in Accounts Payable | 1,901 | 1,901 | -1,532 | 1,024 | 1,074 | -482.3 | Upgrade
|
| Change in Other Net Operating Assets | -337.69 | -337.69 | 125.16 | -47.1 | 850.63 | 1,601 | Upgrade
|
| Operating Cash Flow | 9,713 | 5,820 | 4,842 | 8,107 | 5,779 | 4,905 | Upgrade
|
| Operating Cash Flow Growth | 40.98% | 20.20% | -40.27% | 40.29% | 17.82% | 19.78% | Upgrade
|
| Capital Expenditures | -312.22 | -312.22 | -440.39 | -346.41 | -442.27 | -1,559 | Upgrade
|
| Sale of Property, Plant & Equipment | 44.69 | 44.69 | 14.57 | 11.77 | 1,807 | 35 | Upgrade
|
| Investment in Securities | -1,454 | -1,454 | 9,563 | -18,124 | 2,250 | 920 | Upgrade
|
| Other Investing Activities | -2,784 | 1,612 | -1,156 | 14,080 | 547.26 | 35.55 | Upgrade
|
| Investing Cash Flow | -4,308 | 87.12 | 8,079 | -4,055 | 4,180 | -568.43 | Upgrade
|
| Long-Term Debt Repaid | - | -181.25 | -168.68 | -156.18 | -149.84 | -150.52 | Upgrade
|
| Total Debt Repaid | -181.25 | -181.25 | -168.68 | -156.18 | -149.84 | -150.52 | Upgrade
|
| Net Debt Issued (Repaid) | -181.25 | -181.25 | -168.68 | -156.18 | -149.84 | -150.52 | Upgrade
|
| Common Dividends Paid | -5,416 | -5,416 | -15,255 | -5,066 | -6,770 | -3,388 | Upgrade
|
| Other Financing Activities | -53.89 | -17.99 | -9.55 | -19.9 | -35.31 | -737.57 | Upgrade
|
| Financing Cash Flow | -5,651 | -5,615 | -15,433 | -5,242 | -6,956 | -4,276 | Upgrade
|
| Net Cash Flow | -246.2 | 292.3 | -2,512 | -1,190 | 3,004 | 60.35 | Upgrade
|
| Free Cash Flow | 9,401 | 5,508 | 4,402 | 7,761 | 5,337 | 3,346 | Upgrade
|
| Free Cash Flow Growth | 45.77% | 25.13% | -43.28% | 45.42% | 59.50% | 183.07% | Upgrade
|
| Free Cash Flow Margin | 26.40% | 15.95% | 13.54% | 23.68% | 18.24% | 10.38% | Upgrade
|
| Free Cash Flow Per Share | 55.49 | 32.51 | 25.98 | 45.81 | 31.50 | 19.75 | Upgrade
|
| Cash Interest Paid | 15.75 | 15.75 | 13.98 | 17.37 | 35.31 | 41.14 | Upgrade
|
| Cash Income Tax Paid | 2,349 | 2,349 | 2,646 | 1,195 | 1,474 | 3,107 | Upgrade
|
| Levered Free Cash Flow | 9,923 | 6,701 | 1,562 | 10,097 | 3,506 | 45.42 | Upgrade
|
| Unlevered Free Cash Flow | 9,934 | 6,712 | 1,573 | 10,109 | 3,528 | 85.02 | Upgrade
|
| Change in Net Working Capital | -3,453 | -970.13 | 3,347 | -5,341 | 191.63 | 2,983 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.